Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 15/20 | 0.49 |
| ▸ | HRH1 | P35367 | 15/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917449 | 0.91 | HRH3 (0.54) | HRH3ADRA1AHRH1ADRA1BKCNH2 | |
| SCHEMBL9917477 | 0.89 | SPHK1 (0.48) | HRH3ADRA1AHRH1ADRA1BKCNH2 | |
| SCHEMBL9917473 | 0.88 | SPHK2 (0.45) | HRH3ADRA1AHRH1ADRA1BKCNH2 | |
| SCHEMBL9917447 | 0.86 | HRH3 (0.52) | HRH3ADRA1AHRH1ADRA1BKCNH2 | |
| SCHEMBL9917472 | 0.85 | HRH3 (0.55) | HRH3KCNH2 | |
| SCHEMBL9917481 | 0.85 | HRH3 (0.55) | HRH3KCNH2 | |
| SCHEMBL9917525 | 0.84 | HRH3 (0.52) | HRH3HRH1HRH2 | |
| SCHEMBL9921255 | 0.81 | SLC6A9 (0.42) | HRH3ADRA1AKCNH2CYP2D6 | |
| SCHEMBL9917530 | 0.80 | HRH3 (0.43) | HRH3ADRA1AHRH1ADRA1BKCNH2 | |
| SCHEMBL9917513 | 0.80 | HRH3 (0.51) | HRH3ADRA1AHRH1ADRA1BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940730-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940730-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-14 | — | — | US | disclosed |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | HRH3 4193/4885ADRA1A 4433/4885HRH1 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.